Bibliography
- BOOTHMAN DA, TRASK DK, PARDEE AB: Inhibition of potentially lethal DNA damage repair in human tumor cells byl3-lapachone, an activator of topoisomerase I. Cancer Res. (1989) 49(3):605–612.
- MATTERN MR, HOFMANN GA, MCCABE FL, JOHNSONRK: Synergistic cell killing by ionizing radiation and topoisomerase I inhibitortopotecan (SK&F 104864). Cancer Res. (1991) 51(21):5813–5816.
- MIYASHITA T, HARIGAI M, HANADA M, REED JC: Identification of a p53 dependent negative response element in the bcl-2 gene. Cancer Res. (1994) 54(12):3131–3135.
- WEINER TM, LIU ET, CRAVEN RJ, CANCE WG: Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors. Ann. Surg. °neut. (1994) 1(1):18–27.
- GAHÈRY-SÈGARD H, MOLINIER- V, LE BOULAIRE C et al.: Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J. Cliii. Investig. (1997) 100:2218–2226.
- HARDY S, KITAMURA M, HARRIS-STANSIL T, DAI Y, PHIPPS ML: Construction of adenovirus vectors through Cm-lox recombination. Viroi (1997) 71(3):1842–1849.
- VERMA IM, SOMIA N: Gene therapy - promises, problems and prospects. Nature (1997) 389(6648):239–242.
- •Review of the obstacles faced when using gene therapy.
- KOCHANEK S, CLEMENS PR, MITANI, CHEN HH, CHAN S, CASKEY CT: A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-lengthdystrophin and P-galactosidase. Proc. NatL Acad. Sci. USA (1996) 93(12):5731–5736.
- ••Describes the production of gutlessadenoviral vectors.
- MORRAL N, O'NEAL W RICE K et aL: of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. USA (1999) 96(22):12816–12821.
- •Interesting article focusing on gutless viral vectors. Describes achievement of long-term gene expression in vivo and addresses the possibility of re-administration of vectors.
- JOOSS K, TURKA LA, WILSON J: Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene The]: (1998) 5(3):309–319.
- WILLCOX N, MAUTNER V: Antigenic determinants of adenovirus capsids. II. Homogeneity of hexons, and accessibility of their determinants, in the virion. Immunol (1976) 116(1):25–29.
- VON SEGGERN DJ, CHIU CY, FLECK SK, STEWART PL, NEMEROW GR: A helper-independent adenovirus vector with El, E3, and fiber deleted: structure and infectivity of fiberless particles. J. Viral. (1999) 73(2):1601–1608.
- TAO N, GAO GP, PARR M et al.: Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. MM. The]: (2001) 3(1):28–35.
- BERGELSON JM, CUNNINGHAM JA, DROGUETT G et al.: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 275(5304):1320–1323.
- HONG SS, KARAYAN L, TOURNIER J, CURIEL DT, BOULANGER PA: Adenovirus Type 5 fiber knob binds to MHC class I a2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J. (1997) 16(9):2294–2306.
- WICKHAM TJ, MATHIAS P, CHERESH DA, NEMEROW GR: Integrins ad33 and aApromote adenovirus internalisation but not virus attachment. Cell (1993) 73(2):309–319.
- WATKINS SJ, MESYANZHINOV VV, KUROCHKINA LP, HAWKINS RE: The `adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene The]: (1997) 4(10):1004–1012.
- NETTELBECK DM, MILLER DW, JEROME V et al: Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). MM. The]: (2001) 3(6):882–891.
- NICKLIN SA, VON SEGGERN DJ, WORK LM et al.: Ablating adenovirus Type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generates an endothelial cell-selective adenovirus. Ma The]: (2001) 4(6):534–542.
- •Methods of retargeting adenovirus through incorporation of targeting sequences.
- FISHER KD, STALLWOOD Y, GREEN NK, ULBRICH K, MAUTNER V, SEYMOUR LW: Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene The]: (2001) 8(5):341–348.
- •Description of a method to modify viral vectors to evade immune recognition and retarget to specific cell types.
- KIM D: Clinical research results with 520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene The]: (2001) 8(2):89–98.
- HEISE C, HERMISTON T, JOHNSON Let al.: An adenovirus E lA mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. (2000) 6(10):1134–1139.
- MANN R, MULLIGAN RC, BALTIMORE D: Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell (1983) 33(1):153–159.
- •Development of retroviral packaging cell lines.
- EMI N, FRIEDMANN T, YEE JK: Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. J. Vim/. (1991) 65(3):1202–1207.
- YEE JK, FRIEDMANN T, BURNS JC: Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol. (1994) 43 (Part A):99–112.
- PALMARINI M, FAN H, SHARP JM: Sheep pulmonary adenomatosis: a unique of retrovirus-associated lung cancer. Trends Microbiol (1997) 5(12):478–483.
- DE LAS HERAS M, BARSKY SH, HASLETON P et al.: Evidence for a protein related immunologically to the jaagsiekte sheep retrovirus in some human lung tumours. Eur. Respir. J (2000) 16(2):330–332.
- TRONO D: Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene The]: (2000) 7(1):20–23.
- •Review outlining the development of lentiviral vectors for gene therapy.
- BUKRINSKY MI, SHAROVA N, DEMPSEY MP et al.: Active nuclear import of human immunodeficiency virus Type 1 preintegration complexes. Proc. Natl. Acad. Sci. USA (1992) 89(14):6580–6584.
- BUKRINSKY MI, HAGGERTY S, DEMPSEY MP et al.: A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature (1993) 365 (6447):666–669.
- NALDINI L, BLOMER U, GALLAY P et al.: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 272(5259):263–267.
- ••First report of the use of HR/-basedlentiviral vectors.
- HALBERT CL, ALEXANDER IE, WOLGAMOT GM, MILLER AD: Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells." Virol. (1995) 69(3):1473–1479.
- OKADA H, MIYAMURA K, ITOH T et al.: Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene The]: (1996) 3 (11):957–964.
- PAILLARD F: Epstein-Barr virus vectors for the treatment of Epstein-Barr virus-associated cancers. Hum. Gene The]: (1998) 9(8):1119–1120.
- DELECLUSE HJ, HILSENDEGEN T, PICH D, ZEIDLER R, HAMMERSCHMIDT W: Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc. Natl. Acad. Sci. USA (1998) 95(14):8245–8250.
- SPECK SH, PFITZNER A, JL: An Epstein-Barr virus transcript from a latently infected, growth-transformed B-cell line encodes a highly repetitive polypeptide. Proc. Nati Acad. Sci. USA (1986) 83(24):9298–9302.
- ARMSTRONG GD, PAUL KW, LEE PW: Studies on reovirus receptors of L cells: virus characteristics and comparison with reovirus receptors of erythrocytes. Virology (1984) 138(1):37–48.
- ARTHUR JF, BUTTERFIELD LH, ROTH MD et al.: A comparison of gene transfer methods in human dendritic cells. Gene Ther. (1997) 4:17–25.
- DOUGLAS JT, ROGERS BE, ME, MICHAEL SI, FENG, CURIEL DT: Targeted gene delivery by tropism modified adenoviral vectors. Nat. Biotechnol (1996) 14:1574–1578.
- ••The first demonstration of the retargetingof a recombinant adenoviral vector via a non-adenoviral cellular receptor, using the folate receptor.
- WICKHAM TJ, SEGAL DM, PW et al: Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies.' Virol (1996) 70:6831–6838.
- ••Demonstrates that adenoviral vectors canbe targeted to specific receptors by the use of bispecfic antibodies, which increases the efficiency of gene transfer.
- TILLMAN BW, DE GRUIJL TD, LUYKX-DE BAKKER SA et al.: of dendritic cells accompanies high-efficiency gene transfer by a CD40- adenoviral vector. " bronunol (1999) 162(11):6378–6383.
- WALLACK MK, SIVANANDHAM M, BALCH CM et al: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a Phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J. Am. Coll. Surg. (1998) 187(1):69–77.
- LILLEY CE, GROUTSI F, HAN Z et al: Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo. J. Virol (2001) 75(9):4343–4356.
- CHOU J, KERN ER, WHITLEY RJ, ROIZMAN B: Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. (1990) 250(4985):1262–1266.
- MARKERT JM, GILLESPIE GY, WEICHSELBAUM RR, ROIZMAN B, WHITLEY RI: Genetically engineered HSV in the treatment of glioma: a review. Rev Med. Virol (2000) 10(1):17–30.
- •Review of the use of HSV for the treatment of glioma.
- PARKER IN, GILLESPIE GY, LOVE CE, S, WHITLEY RI, MARKERT: Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl. Acad. Sd. USA (2000) 97(5):2208–2213.
Websites
- Journal of Gene Medicine, clinical trials database; www.wiley.co.uk/genetherapy-clinical